Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones

被引:0
|
作者
Zhang, Fan [1 ,2 ,3 ]
Li, Wenjian [1 ,4 ]
机构
[1] Xuzhou Med Univ, Changzhou Clin Coll, Changzhou, Peoples R China
[2] Changzhou Third Peoples Hosp, Dept Endocrinol, Changzhou, Peoples R China
[3] Changzhou Third Peoples Hosp, Dept Clin Nutr, Changzhou, Peoples R China
[4] Changzhou Third Peoples Hosp, Dept Urol, Changzhou, Peoples R China
关键词
Fatty liver index; Metabolic dysfunction-associated steatotic liver disease; Kidney stones; Risk factors; NHANES; BODY-MASS INDEX; NEPHROLITHIASIS; PATHOGENESIS; NAFLD;
D O I
10.1159/000543404
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data. Methods: This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses. Results: The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI. Conclusion: This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.
引用
收藏
页码:115 / 130
页数:16
相关论文
共 50 条
  • [1] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [2] Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly
    Lan, Yanqi
    Guo, Zhinan
    Dai, Junsheng
    Chen, Kailin
    Chen, Youlan
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1557 - 1564
  • [3] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [4] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [5] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [6] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [7] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [8] Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?
    Cunneely, Owen P.
    Roberts, Anne
    Fargue, Sonia
    Knight, John
    Assimos, Dean G.
    Wood, Kyle D.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2025, 34 (03) : 247 - 253
  • [9] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01)
  • [10] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    Diabetology & Metabolic Syndrome, 14